JP2017081972A5 - - Google Patents

Download PDF

Info

Publication number
JP2017081972A5
JP2017081972A5 JP2017000107A JP2017000107A JP2017081972A5 JP 2017081972 A5 JP2017081972 A5 JP 2017081972A5 JP 2017000107 A JP2017000107 A JP 2017000107A JP 2017000107 A JP2017000107 A JP 2017000107A JP 2017081972 A5 JP2017081972 A5 JP 2017081972A5
Authority
JP
Japan
Prior art keywords
composition
mesenchymal stem
stem cells
pharmaceutically acceptable
serum albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017000107A
Other languages
English (en)
Other versions
JP2017081972A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017081972A publication Critical patent/JP2017081972A/ja
Publication of JP2017081972A5 publication Critical patent/JP2017081972A5/ja
Pending legal-status Critical Current

Links

Claims (17)

  1. 精製済み間葉系幹細胞を含む薬学的に許容しうる組成物であって、一つまたはそれを超える間葉系幹細胞集合体を含み、そして該集合体のＤ９０が、約１５０μｍ未満である薬学的に許容しうる組成物。
  2. 前記集合体のＤ９０が、約１００μｍ未満である、請求項１に記載の薬学的に許容しうる組成物。
  3. 前記集合体のＤ９０が、約５０μｍ未満である、請求項２に記載の薬学的に許容しうる組成物。
  4. 精製済み間葉系幹細胞の生存能力が、約７０％より大である、請求項１に記載の薬学的に許容しうる組成物。
  5. 精製済み間葉系幹細胞の生存能力が、約８０％より大である、請求項４に記載の薬学的に許容しうる組成物。
  6. 精製済み間葉系幹細胞を含む薬学的に許容しうる組成物であって、約５５μｇ／ｍＬ未満の残留ウシ血清アルブミンを含み、そしてここにおいて、間葉系幹細胞が、約１８μｍ〜約３０μｍのＤ９０を示す薬学的に許容しうる組成物。
  7. 組成物が、約４２μｇ／ｍＬ未満の残留ウシ血清アルブミンを含む、請求項６に記載の組成物。
  8. 組成物が、約２５μｇ／ｍＬ未満の残留ウシ血清アルブミンを含む、請求項７に記載の組成物。
  9. 組成物が、約１３μｇ／ｍＬ未満の残留ウシ血清アルブミンを含む、請求項８に記載の組成物。
  10. 組成物が、約１０μｇ／ｍＬ未満の残留ウシ血清アルブミンを含む、請求項９に記載の組成物。
  11. 組成物が、約７μｇ／ｍＬ〜約１５μｇ／ｍＬの残留ウシ血清アルブミンを含む、請求項６に記載の組成物。
  12. 組成物が、約８μｇ／ｍＬ〜約１２μｇ／ｍＬの残留ウシ血清アルブミンを含む、請求項１１に記載の組成物。
  13. 間葉系幹細胞が、約１８μｍ〜約２５μｍのＤ９０を示す、請求項６に記載の組成物。
  14. 精製済み間葉系幹細胞の生存能力が、約７０％より大である、請求項６に記載の組成物。
  15. 精製済み間葉系幹細胞の生存能力が、約８０％より大である、請求項１４に記載の組成物。
  16. 免疫応答、肺塞栓症、血管収縮、または心臓性ショックの予防または治療に有用な医薬としての、請求項１〜１４のいずれか一項に記載の組成物。
  17. 該予防または治療が、免疫原性の増加およびレシピエントからの間葉系幹細胞のクリアランスまたは***の促進を防ぐ、請求項１６に記載の組成物。
JP2017000107A 2008-08-14 2017-01-04 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法 Pending JP2017081972A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8889808P 2008-08-14 2008-08-14
US61/088,898 2008-08-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014224180A Division JP2015071610A (ja) 2008-08-14 2014-11-04 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018036415A Division JP2018109052A (ja) 2008-08-14 2018-03-01 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法

Publications (2)

Publication Number Publication Date
JP2017081972A JP2017081972A (ja) 2017-05-18
JP2017081972A5 true JP2017081972A5 (ja) 2017-09-21

Family

ID=41669330

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011523195A Active JP6025329B2 (ja) 2008-08-14 2009-08-14 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2014224180A Pending JP2015071610A (ja) 2008-08-14 2014-11-04 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2017000107A Pending JP2017081972A (ja) 2008-08-14 2017-01-04 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2018036415A Pending JP2018109052A (ja) 2008-08-14 2018-03-01 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2020072934A Pending JP2020120671A (ja) 2008-08-14 2020-04-15 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2023000381A Pending JP2023052211A (ja) 2008-08-14 2023-01-05 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011523195A Active JP6025329B2 (ja) 2008-08-14 2009-08-14 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2014224180A Pending JP2015071610A (ja) 2008-08-14 2014-11-04 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018036415A Pending JP2018109052A (ja) 2008-08-14 2018-03-01 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2020072934A Pending JP2020120671A (ja) 2008-08-14 2020-04-15 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
JP2023000381A Pending JP2023052211A (ja) 2008-08-14 2023-01-05 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法

Country Status (14)

Country Link
US (5) US8637004B2 (ja)
EP (2) EP2318519B1 (ja)
JP (6) JP6025329B2 (ja)
AR (2) AR073069A1 (ja)
AU (1) AU2009281809B2 (ja)
BR (1) BRPI0917993B8 (ja)
CA (1) CA2733985C (ja)
DK (1) DK2318519T3 (ja)
ES (1) ES2608974T3 (ja)
IL (1) IL211214A0 (ja)
MX (2) MX362512B (ja)
NZ (2) NZ591146A (ja)
WO (1) WO2010019886A1 (ja)
ZA (1) ZA201101858B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461884A1 (en) 2004-03-22 2019-04-03 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
MX2008008774A (es) 2006-01-13 2008-09-26 Osiris Therapeutics Inc Celulas madre mesenquimales que expresan los receptores tnf-alfa.
MX362512B (es) 2008-08-14 2019-01-22 Mesoblast Int Sarl Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
CN105766891A (zh) 2008-08-20 2016-07-20 人类起源公司 改进的细胞组合物及制备所述组合物的方法
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
EP2624846A2 (en) 2010-10-08 2013-08-14 Osiris Therapeutics, Inc. Nanoparticle-loaded cells
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
ITGE20120034A1 (it) * 2012-03-28 2013-09-29 Carlo Tremolada Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
JP2013252126A (ja) * 2012-05-08 2013-12-19 Otsuka Pharmaceut Factory Inc デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
EP2970882B1 (en) 2013-03-15 2018-11-28 AlloSource Cell repopulated collagen matrix for soft tissue repair and regeneration
CN105793411B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3238760B1 (en) * 2016-04-29 2019-10-02 Fenwal, Inc. System and method for selecting and culturing cells
US10251990B2 (en) 2016-04-29 2019-04-09 Fenwal, Inc. System and method for processing, incubating, and/or selecting biological cells
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10274495B2 (en) 2016-12-21 2019-04-30 Fenwal, Inc. System and method for separating cells incorporating magnetic separation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US20210395693A1 (en) * 2018-10-26 2021-12-23 Guy MARTI Method and apparatus for mesenchymal stem cells isolation and purification
US20220175674A1 (en) * 2019-05-15 2022-06-09 Stemcyte Inc. High concentration cell packaging and shipping
WO2021144995A1 (ja) * 2020-01-16 2021-07-22 ＰｕＲＥＣ株式会社 高純度間葉系幹細胞

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
JP2881305B2 (ja) 1986-08-11 1999-04-12 バクスター、インターナショナル、インコーポレイテッド 血球洗浄システムおよび方法
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5234608A (en) 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
CA2192103C (en) * 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
EP2311471A3 (en) * 1996-04-19 2013-05-15 Osiris Therapeutics, Inc. Regeneration and augmentation of bone using mesenchymal stem cells
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) * 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
DK1066052T3 (da) 1998-03-18 2006-06-12 Osiris Therapeutics Inc Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer
FR2787463B1 (fr) 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2003053346A2 (en) * 2001-12-07 2003-07-03 Macropore Biosurgery, Inc. Systems and methods for treating patients with processed lipoaspirate cells
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US8105580B2 (en) * 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
ZA200404101B (en) 2003-05-26 2005-03-07 Reliance Life Sciences Pvt Ltd In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
WO2005012480A2 (en) 2003-06-25 2005-02-10 Macropore Biosurgery Inc. Systems and methods for separating and concentrating regenerative cells from tissue
EP3461884A1 (en) 2004-03-22 2019-04-03 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP3828905B2 (ja) * 2004-08-05 2006-10-04 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ 局所麻酔薬を含有する細胞凝集抑制剤
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
WO2007035843A2 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7888119B2 (en) * 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
EP1984488B1 (en) 2006-01-30 2017-12-27 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
CN101448527B (zh) 2006-05-19 2013-12-18 香港大学 细胞-基质微球，制备方法和应用
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
JP5537153B2 (ja) 2006-11-03 2014-07-02 アストロム バイオサイエンシーズ， インコーポレイテッド 組織修復のための混合細胞集団および細胞処理のための単離技術
JP2008139106A (ja) * 2006-11-30 2008-06-19 Sysmex Corp 骨髄穿刺液収容具及び骨髄穿刺液濾過方法
WO2008073331A2 (en) 2006-12-07 2008-06-19 Teva Pharmaceutical Industries Ltd. Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue
US20110262402A1 (en) 2007-09-07 2011-10-27 Masahiko Kuroda Therapeutic and prophylactic agents for arthritis
US8465733B2 (en) 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
MX362512B (es) 2008-08-14 2019-01-22 Mesoblast Int Sarl Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
US8048976B2 (en) 2008-09-04 2011-11-01 Amyris, Inc. Polyfarnesenes

Similar Documents

Publication Publication Date Title
JP2018109052A5 (ja)
JP2017081972A5 (ja)
Antunes et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema
JP2018193377A5 (ja)
JP2015517489A5 (ja)
JP2018520997A5 (ja)
WO2015120110A3 (en) Novel pharmaceutical formulations
NZ591146A (en) Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
JP2005524658A5 (ja)
JP2016534142A5 (ja)
JP2016523285A5 (ja)
MA33374B1 (fr) Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
WO2009040048A3 (en) Use of the c-reactive peptide as a therapeutic agent
JP2014527040A5 (ja)
JP2016507526A5 (ja)
JP2014509319A5 (ja)
JP2017141225A5 (ja)
JP2016537414A5 (ja)
RU2015139758A (ru) Хиназолины в качестве ингибиторов киназы
JP2014533681A5 (ja)
MX351059B (es) Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
MX2020011474A (es) Nuevo tratamiento de enfermedades pulmonares intersticiales.
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
JP2018039810A5 (ja)
CO6630127A2 (es) Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar